Anacor Pharms Inc Drug Patent Portfolio
Anacor Pharms Inc owns 2 orange book drugs protected by 19 US patents Given below is the list of Anacor Pharms Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8168614 | Boron-containing small molecules as anti-inflammatory agents | 20 Jul, 2030 | Active |
US8168614 | Boron-containing small molecules as anti-inflammatory agents | 20 Jan, 2030 | Active |
US8039451 | Boron-containing small molecules | 29 Dec, 2029 | Active |
US8039451 | Boron-containing small molecules | 29 Jun, 2029 | Active |
US7582621 | Boron-containing small molecules | 26 Nov, 2027 | Active |
US8501712 | Boron-containing small molecules as anti-inflammatory agents | 16 Aug, 2027 | Active |
US9682092 | Boron-containing small molecules as anti-inflammatory agents | 16 Aug, 2027 | Active |
US7582621 | Boron-containing small molecules | 26 May, 2027 | Active |
US7767657 | Boron-containing small molecules | 22 May, 2027 | Active |
US8501712 | Boron-containing small molecules as anti-inflammatory agents | 16 Feb, 2027 | Active |
US9682092 | Boron-containing small molecules as anti-inflammatory agents | 16 Feb, 2027 | Active |
US9549938 | Boron-containing small molecules | 16 Aug, 2026 | Active |
US9566289 | Boron-containing small molecules | 16 Aug, 2026 | Active |
US9566290 | Boron-containing small molecules | 16 Aug, 2026 | Active |
US9572823 | Boron-containing small molecules | 16 Aug, 2026 | Active |
US9549938 | Boron-containing small molecules | 16 Feb, 2026 | Active |
US9566289 | Boron-containing small molecules | 16 Feb, 2026 | Active |
US9566290 | Boron-containing small molecules | 16 Feb, 2026 | Active |
US9572823 | Boron-containing small molecules | 16 Feb, 2026 | Active |
Latest Legal Activities on Anacor Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Anacor Pharms Inc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 12 Oct, 2023 | US8168614 |
Payment of Maintenance Fee, 12th Year, Large Entity | 09 Mar, 2023 | US8039451 |
Application Return TO OIPE | 18 Jul, 2022 | US9566290 |
Application Return from OIPE | 18 Jul, 2022 | US9566290 |
Correspondence Address Change
Critical
| 18 Jul, 2022 | US9566290 |
Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7767657 |
Patent Term Extension Certificate
Critical
| 10 Dec, 2021 | US8039451 |
Maintenance Fee Reminder Mailed
Critical
| 19 Apr, 2021 | US7582621 |
Review Certificate Mailed | 16 Apr, 2021 | US9572823 |
Review Certificate Mailed | 08 Apr, 2021 | US9566289 |
Review Certificate Mailed | 08 Apr, 2021 | US9566290 |
Review Certificate Mailed | 08 Apr, 2021 | US9549938 |
Review Certificate | 19 Mar, 2021 | US9549938 |
Review Certificate | 19 Mar, 2021 | US9566290 |
Review Certificate | 19 Mar, 2021 | US9566289 |
Anacor Pharms Inc's Drug Patent Litigations
Anacor Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 20, 2015, against patent number US7767657. The petitioner Coalition for Affordable Drugs X, LLC, challenged the validity of this patent, with Anacor Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Anacor Pharms Inc's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US9549938 | November, 2017 |
FWD Entered
(05 Jun, 2019)
| Anacor Pharmaceuticals, Inc. | FlatWing Pharmaceuticals, LLC |
US9566289 | November, 2017 |
FWD Entered
(05 Jun, 2019)
| Anacor Pharmaceuticals, Inc. | FlatWing Pharmaceuticals, LLC |
US9566290 | November, 2017 |
FWD Entered
(05 Jun, 2019)
| Anacor Pharmaceuticals, Inc. | FlatWing Pharmaceuticals, LLC |
US9572823 | November, 2017 |
FWD Entered
(05 Jun, 2019)
| Anacor Pharmaceuticals, Inc. | FlatWing Pharmaceuticals, LLC |
US9549938 | July, 2018 |
Terminated
(11 Oct, 2018)
| Pfizer Inc. | Mylan Pharmaceuticals Inc. et al. |
US9566289 | July, 2018 |
Terminated
(11 Oct, 2018)
| Pfizer Inc. | Mylan Pharmaceuticals Inc. et al. |
US9566290 | July, 2018 |
Terminated
(11 Oct, 2018)
| Pfizer Inc. | Mylan Pharmaceuticals Inc. et al. |
US9572823 | July, 2018 |
Terminated
(11 Oct, 2018)
| Pfizer Inc. | Mylan Pharmaceuticals Inc. et al. |
US7582621 | August, 2015 |
FWD Entered
(23 Feb, 2017)
| Anacor Pharmaceuticals, Inc. | Coalition for Affordable Drugs X LLC |
US7767657 | August, 2015 |
FWD Entered
(23 Feb, 2017)
| Anacor Pharmaceuticals, Inc. | Coalition for Affordable Drugs X, LLC |
Anacor Pharms Inc's Family Patents
Anacor Pharms Inc Drug List
Given below is the complete list of Anacor Pharms Inc's drugs and the patents protecting them.
1. Eucrisa
Eucrisa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8168614
(Pediatric)
| Boron-containing small molecules as anti-inflammatory agents |
20 Jul, 2030
(5 years from now)
| Active |
US8168614 | Boron-containing small molecules as anti-inflammatory agents |
20 Jan, 2030
(5 years from now)
| Active |
US8039451
(Pediatric)
| Boron-containing small molecules |
29 Dec, 2029
(5 years from now)
| Active |
US8039451 | Boron-containing small molecules |
29 Jun, 2029
(4 years from now)
| Active |
US8501712
(Pediatric)
| Boron-containing small molecules as anti-inflammatory agents |
16 Aug, 2027
(2 years from now)
| Active |
US9682092
(Pediatric)
| Boron-containing small molecules as anti-inflammatory agents |
16 Aug, 2027
(2 years from now)
| Active |
US8501712 | Boron-containing small molecules as anti-inflammatory agents |
16 Feb, 2027
(2 years from now)
| Active |
US9682092 | Boron-containing small molecules as anti-inflammatory agents |
16 Feb, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eucrisa's drug page
2. Kerydin
Kerydin is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7582621
(Pediatric)
| Boron-containing small molecules |
26 Nov, 2027
(3 years from now)
| Active |
US7582621 | Boron-containing small molecules |
26 May, 2027
(2 years from now)
| Active |
US7767657 | Boron-containing small molecules |
22 May, 2027
(2 years from now)
| Active |
US9549938
(Pediatric)
| Boron-containing small molecules |
16 Aug, 2026
(1 year, 10 months from now)
| Active |
US9566289
(Pediatric)
| Boron-containing small molecules |
16 Aug, 2026
(1 year, 10 months from now)
| Active |
US9566290
(Pediatric)
| Boron-containing small molecules |
16 Aug, 2026
(1 year, 10 months from now)
| Active |
US9572823
(Pediatric)
| Boron-containing small molecules |
16 Aug, 2026
(1 year, 10 months from now)
| Active |
US9549938 | Boron-containing small molecules |
16 Feb, 2026
(1 year, 4 months from now)
| Active |
US9566289 | Boron-containing small molecules |
16 Feb, 2026
(1 year, 4 months from now)
| Active |
US9566290 | Boron-containing small molecules |
16 Feb, 2026
(1 year, 4 months from now)
| Active |
US9572823 | Boron-containing small molecules |
16 Feb, 2026
(1 year, 4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kerydin's drug page